Treatment of ALK - Positive Non-Small Cell Lung Cancer: Current Status & Future Directions

Overview

This webinar will update attendees on recent clinical trials with ALK-tyrosine kinase inhibitors (TKIs) in patients with ALK-rearranged NSCLC. It will address choice of optimal first line therapy, as well as strategies to deal with acquired resistance to first and second generation ALK TKIs.

Following the presentation, there will be ample time for discussion and a question/answer session.  Attendees will be able to submit questions and comments to Dr. Solomon and Dr. Govindan via internet chat.

Date
Jun 26, 2018 -
Jun 26, 2018
Location

Online

After attendind this webinar learners will be able to:

  • Review the current data relative to the treatment of Stage IV ALK-positive non-small cell lung cancer (NSCLC).
  • Discuss and review treatment strategies to deal with acquired resistance to first and second generation ALK- tyrosine kinase inhibitors (TKIs).
  • Identify and discuss ongoing and planned clinical trials most likely to impact treatment in the future.

For any inquiries, please contact [email protected].

After attendind this webinar learners will be able to:

  • Review the current data relative to the treatment of Stage IV ALK-positive non-small cell lung cancer (NSCLC).
  • Discuss and review treatment strategies to deal with acquired resistance to first and second generation ALK- tyrosine kinase inhibitors (TKIs).
  • Identify and discuss ongoing and planned clinical trials most likely to impact treatment in the future.

For any inquiries, please contact [email protected].

Share